Physician profile
Edward Somma
NPI 1316954563
$3,425.61
in general payments reported to CMS, 2019-2025
24 companies · $77.71 in 2025
The $77.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $395 · 2021: $642 · 2022: $862 · 2023: $297 · 2024: $262 · 2025: $77.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $643.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $549.47 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $462.59 | 2019-2024 | |
| Lilly USA, LLC | $423.37 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $204.78 | 2019-2023 | Freestyle Libre 3 |
| Amgen INC. | $170.30 | 2023-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $160.68 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $119.82 | 2019-2021 | |
| Senseonics, Incorporated | $85.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.80 | 2019-2021 | |
| Dexcom, INC. | $65.86 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $60.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $52.37 | 2019-2022 | |
| Abbvie INC. | $50.16 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $40.87 | 2021-2024 | Breztri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $38.85 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $38.80 | 2019-2021 | |
| Allergan, INC. | $35.19 | 2019-2020 | |
| Althera Pharmaceuticals LLC | $32.85 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $31.31 | 2021-2022 | |
| Pfizer INC. | $28.66 | 2020-2021 | |
| C2n Diagnostics, LLC | $28.64 | 2025 | Precivityad2 |
| Phadia US INC. | $16.36 | 2024 | Immunocap |
| Arbor Pharmaceuticals, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Somma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.